Researchers at the University of Toronto have developed a PET imaging technique that detects biomarkers for chronic traumatic encephalopathy in living people [1, 2].
This development is significant because CTE has historically only been diagnosable after death through brain tissue examination. The ability to identify the disease in living individuals allows for earlier medical intervention, more precise disease monitoring, and improved research into prevention strategies [1, 2].
Led by Dr. John Smith at the University of Toronto’s Brain Imaging Centre, the team created a first-in-class tracer designed to target specific tau aggregates associated with the condition [1, 2]. The results of the study were announced on May 31, 2026 [1].
In a pilot study involving 30 former athletes, the new PET tracer demonstrated a sensitivity of 92% [1, 3] and a specificity of 88% [1]. These figures suggest the tool can reliably distinguish CTE markers from other neurological conditions.
"This is a major step toward diagnosing CTE in living patients," Smith said [1].
Dr. Emily Chen, a contributing team member, noted the technical precision of the approach. "Our PET tracer shows high affinity for tau aggregates associated with CTE, giving us a reliable in-vivo biomarker," Chen said [2].
The research team focused on creating a tool that could be used clinically to help athletes and military veterans who have experienced repetitive head trauma. By visualizing the accumulation of tau proteins, the hallmark of CTE, clinicians may soon be able to track the progression of the disease in real time [1, 2].
“This is a major step toward diagnosing CTE in living patients.”
The shift from post-mortem diagnosis to in-vivo detection transforms CTE from a retrospective finding into a manageable clinical condition. If validated in larger cohorts, this imaging technique could establish a standardized diagnostic protocol for head trauma, potentially influencing safety regulations in professional sports and military training.
